This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Gilead's (GILD) CAR T Cell Therapy Tecartus Wins EC Nod
by Zacks Equity Research
Gilead (GILD) company, Kite, gets conditional marketing authorization for CAR T cell therapy, Tecartus.
Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal
by Zacks Equity Research
Gilead (GILD) decides to not pursue FDA approval of filgotinib for the treatment of RA.
Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.
Lilly (LLY) Stock Up on Raised 2020 View, Upbeat 2021 Guidance
by Zacks Equity Research
Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.
Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $59.84, moving -1.51% from the previous trading session.
Glaxo's (GSK) Rukobia Gets CHMP Nod for Heavily Pre-Treated HIV
by Zacks Equity Research
Glaxo (GSK) receives positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rukobia for treating HIV-1 infection in heavily pre-treated adult HIV patients.
Gilead (GILD) to Buy MYR GmbH for EUR1.15 Billion in Cash
by Zacks Equity Research
Gilead (GILD) will purchase MYR GmbH for EUR1.15 billion and add HDV treatment Hepcludex to its portfolio.
Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $60.82 in the latest trading session, marking a -0.57% move from the prior day.
Fate (FATE) Surges on Favorable Phase I Data on FT596 at ASH
by Zacks Equity Research
Fate (FATE) stock up on positive data from its early-stage study on its NK cell product candidate at ASH.
Aligos (ALGS) Inks Collaboration With Merck for NASH Therapy
by Zacks Equity Research
Aligos (ALGS) signs an exclusive research collaboration agreement with Merck to discover and develop an oligonucleotide therapy for NASH. Shares rise.
Gilead's (GILD) Kite Presents Data on CAR T Cell Therapy at ASH
by Zacks Equity Research
Gilead (GILD) posts positive data on CAR T Cell Therapy Yescarta from multiple studies at ASH.
Lilly (LLY)/UnitedHealth Launch COVID-19 Study on Bamlanivimab
by Zacks Equity Research
The pragmatic study by Lilly (LLY) and UnitedHealth Group (UNH) is set to evaluate bamlanivimab in high-risk symptomatic patients who test positive for COVID-19
Lilly (LLY) to Supply More Doses of COVID-19 Antibody to US
by Zacks Equity Research
With the latest purchase of 6,50,000 additional doses, the U.S. government acquires a total of 9,50,000 doses of bamlanivimab from Eli Lilly (LLY).
COVID-19 Vaccine Race Heats Up: Drugmarkers on Final Lap
by Ritujay Ghosh
Shares of Moderna, Inc. (MRNA), Pfizer, Inc. (PFE) and AstraZeneca plc (AZN) are poised for substantial gains on encouraging final-stage trial results.
Liquidia (LQDA) PAH Drug Gets FDA's Complete Response Letter
by Zacks Equity Research
The CRL issued to the NDA for Liquidia's (LQDA) LIQ861 stated that the FDA cannot approve the NDA in its present form
Biotech Stock Roundup: REGN's Cocktail Gets EUA, GILD & AMGN Provide Updates & More
by Zacks Equity Research
Pipeline and regulatory updates take centerstage in the biotech sector as Regeneron (REGN) and Gilead Sciences (GILD), among others, provide updates on their pipeline candidates.
Regeneron's (REGN) Cocktail Gets EUA for COVID-19 by FDA
by Zacks Equity Research
Regeneron's (REGN) antibody cocktail gets Emergency Use Authorization by the FDA for the treatment of COVID-19.
The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead, Eli Lilly, Incyte and Pfizer
Lilly's (LLY) Coronavirus Treatment Gets Interim Nod in Canada
by Zacks Equity Research
Lilly's (LLY) antibody drug bamlanivimab wins interim authorization from Health Canada to treat COVID-19. The company inks a genome editing research collaboration deal with Precision BioSciences.
AstraZeneca's (AZN) sBLA for New Imfinzi Dosage Gets Approval
by Zacks Equity Research
AstraZeneca's (AZN) Imfizni is now available in monthly, fixed-dose regimen as alternative to twice-monthly, weight-based regimen for all three approved indications.
Gilead (GILD) Down on COVID-19 Drug Remdesivir Update
by Zacks Equity Research
Gilead's (GILD) remdesivir should not be used for hospitalized COVID-19 patients, as per the WHO's conditional recommendation.
Lilly/Incyte's Olumiant Gets FDA Emergency Nod for COVID-19
by Zacks Equity Research
Lilly's (LLY) rheumatoid arthritis drug, Olumiant gets Emergency Use Authorization for treating hospitalized COVID-19 patients in combination with Gilead's Veklury.
Gilead (GILD) Reports Positive Top-Line Data on HIV Candidate
by Zacks Equity Research
Gilead (GILD) announces successful top-line results from a phase I/II study on its investigational, long-acting HIV-1 capsid inhibitor.
Should Value Investors Choose Gilead Sciences (GILD) Stock?
by Zacks Equity Research
Let's see if Gilead Sciences (GILD) stock is a good choice for value-oriented investors right now from multiple angles.
What Awaits Pharma Giants in Last Lap of COVID-19 Vaccine Race?
by Ritujay Ghosh
Pfizer, Inc. (PFE), BioNTech SE (BNTX), Eli Lilly and Company (LLY), AstraZeneca plc (AZN), Moderna, Inc. (MRNA) and Gilead Sciences, Inc. (GILD) are leading the race to come up with a vaccine for coronavirus.